Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized Phase II, placebo-controlled trial

Please use this identifier to cite or link to this item: https://doi.org/10.1080/21645515.2020.1861875

Title:	Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized Phase II, placebo-controlled trial
Authors:	Eujung Juliana Park SOPHIA ARCHULETA May-Lin Helen Oh LYNETTE PEI-CHI SHEK Hao Wang Matthew Bonaparte Carina Frago Alain Bouckenooghe Frederique Jantet-Blaudez Sarah Begue Sophie Gimenez-Fourage Anke Pagnon
Issue Date:	24-Feb-2021
Publisher:	Taylor & Francis
Citation:	Eujung Juliana Park, SOPHIA ARCHULETA, May-Lin Helen Oh, LYNETTE PEI-CHI SHEK, Hao Wang, Matthew Bonaparte, Carina Frago, Alain Bouckenooghe, Frederique Jantet-Blaudez, Sarah Begue, Sophie Gimenez-Fourage, Anke Pagnon (2021-02-24). Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized Phase II, placebo-controlled trial. Human Vaccines & Immunotherapeutics 17 (7) : 2107-2116. ScholarBank@NUS Repository. https://doi.org/10.1080/21645515.2020.1861875
Source Title:	Human Vaccines & Immunotherapeutics
URI:	https://scholarbank.nus.edu.sg/handle/10635/194505
ISSN:	21645515
DOI:	10.1080/21645515.2020.1861875
Appears in Collections:	Staff Publications Elements

File	Description	Size	Format	Access Settings	Version
10.108021645515.2020.1861875.zip		3.88 MB	ZIP	OPEN	Published	View/Download

Check